On a recent Sunday afternoon in lower Manhattan, a small shop inside the Oculus, a soaring curvilinear mall at the World ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

A drug that outperforms placebo in helping people to lose weight is one of a growing number of next-generation obesity drugs being produced in China. At first, Chinese pharmaceutical companies rushed ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Objectives In December 2018, China launched national volume-based procurement (NVBP) to negotiate drug prices with manufacturers. Gefitinib was one of the 25 pilot drugs, which is used for treatment ...

[North Americans] not only are the largest consumers of nitazines, but really have the biggest problem as it relates to the ...

Through June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as US$80 million into ...

(Reuters) -U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 ...

China's share of global drug development is now nearly 30%, while the US share of the world's research and development has slipped 1% to about 48%, ...

China's share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, ...